Biomarkers of failing right ventricle
Total bioartificial lung - devices development
Clinical trials
WORK PACKAGE 1
Work Package 1 (WP), under the leadership of Pr Marc HUMBERT (AP-HP), aims to develop markers of failing Right Ventricle (RV) for a better understanding of the disease and a better selection of patient before therapy (biomarkers, and functional imaging). This WP is divided in three tasks.
TASK 1
“Right ventricular function biomarkers” under the leadership of Pr Elie FADEL (HML), aims:
​
-
To determine whether circulating biomarkers may discriminate the extent of interstitial fibrosis in patients with RV pressure overload
-
To determine how inflammasome activation can contribute to maladaptive remodeling of right ventricle
-
To develop a novel nanotechnology based platform combining the markers of highest yield as determined by previous objectives
TASK 2
“Pulmonary Hypertension Prognosis Biomarkers” under the leadership of Pr Marc HUMBERT (AP-HP) and Pr Olivier SITBON (AP-HP), aims to discover biomarkers predicting survival in a pulmonary arterial hypertension national cohort.
TASK 3
“A new marker of altered RV metabolism” under the leadership of Christophe JUNOT (CEA LEMM), aims to identify novel targets for metabolic, functional imaging of the RV.
WORK PACKAGE 2
Work Package 2 (WP), under the leadership of Pr Olaf MERCIER (HML), aims to specify, design, develop and tests all sub systems which will be integrated to build the total artificial lung. This WP is divided in six tasks.
TASK 1
“BioArt-Lung cannula”, under the leadership of Pr Olaf MERCIER (HML), aims to develop a novel double lumens cannula for Right to left atrial extracorporeal circulation.
TASK 3
TASK 2
“Pump, Tubing and Coating”, under the leadership of Pr Olaf MERCIER (HML), aims to develop the next generation of pump, tubing and coating for prolonged extracorporeal support.
“Oxygenator endothelialization”, under the leadership of Dr Georges UZAN (INSERM U1197), aims to develop a robust endothelial cells that will adapt to specific stress conditions of the novel oxygenator and develop and validate oxygenator cells seeding protocol.
WORK PACKAGE 1
Work Package 1 (WP1), under the leadership of Pr Olivier SITBON (AP HP), aims to develop markers of failing Right Ventricle (RV) for a better understanding of the disease and a better selection of patient before therapy (biomarkers, and functional imaging). This WP is divided in three tasks.
TASK 1
“Right ventricular function biomarkers” under the leadership of Pr Elie FADEL (HML), aims:
​
-
To determine whether circulating biomarkers may discriminate the extent of interstitial fibrosis in patients with RV pressure overload
-
To determine how inflammasome activation can contribute to maladaptive remodeling of right ventricle
-
To develop a novel nanotechnology based platform combining the markers of highest yield as determined by previous objectives
​
TASK 2
“Pulmonary Hypertension Prognosis Biomarkers” under the leadership of Pr Marc HUMBERT (AP-HP) and Pr Olivier SITBON (AP-HP), aims to discover biomarkers predicting survival in a pulmonary arterial hypertension national cohort.
TASK 3
“A new marker of altered RV metabolism” under the leadership of Christophe JUNOT (CEA LEMM), aims to identify novel targets for metabolic, functional imaging of the RV.
TASK 5
WORK PACKAGE 2
Work Package 2 (WP2), under the leadership of Pr Olaf MERCIER (HML), aims to specify, design, develop and tests all sub systems which will be integrated to build the total artificial lung. This WP is divided in six tasks.
TASK 1
“BioArt-Lung cannula”, under the leadership of Pr Olaf MERCIER (HML), aims to develop a novel double lumens cannula for Right to left atrial extracorporeal circulation.
TASK 4
Next generation of oxygenator”, under the leadership of Dr Anne Marie HAGHIRI (CNRS), aims to specify, design, develop and test a novel endothelial oxygenator based on microfluidics technology.
TASK 2
“Pump, Tubing and Coating”, under the leadership of Pr Olaf MERCIER (HML), aims to develop the next generation of pump, tubing and coating for prolonged extracorporeal support.
TASK 3
“Oxygenator endothelialization”, under the leadership of Dr Georges UZAN (INSERM U1197), aims to develop a robust endothelial cells that will adapt to specific stress conditions of the novel oxygenator and develop and validate oxygenator cells seeding protocol.
TASK 6
“Energy autonomy”, under the leadership of Dr Yvan REYNIER (CEA LITEN), aims to specify, design, and develop a portable long-acting battery.
“BioArt-Lung”, under the leadership
of Pr Olaf MERCIER (HML) aims to specify, design and integrate the total Bio-Artificial lung.
WORK PACKAGE 3
Work Package 3 (WP3), under the leadership of Pr Olaf MERCIER (HML), aims to manage, specify, and perform clinical studies and prepare industrial transfer.
TASK 1
“Cannula Clinical trial”, under the leadership of Pr Olaf MERCIER (HML), aims to manage, specify and perform clinical trial for safety and efficacy of the novel cannula.
TASK 2
“Circuit Trial”, under the leadership of Pr Olaf MERCIER (HML), aims to manage, specify and perform clinical trial for safety and efficacy of the novel circuit components
TASK 3
“Bio-Oxygenator trial”, under the leadership of Pr Olaf MERCIER (HML), aims to manage, specify and perform clinical trial for safety and efficacy of the novel bio-oxygenator.
TASK 5
TASK 4
“Bio-markers trail”, under the leadership of Pr Elie FADEL (HML), aims to manage, specify and perform clinical trial to validate blood biomarkers and new imaging tracers to predict outcomes and RV function in patients with severe PH.
“BioArt-Lung trial”, under the leadership of Pr Olaf MERCIER (HML), aims to manage, specify and perform clinical trial for safety and efficacy of the total Bio-Artificial lung.
PUBLICATIONS
I’m a paragraph. Double click here or click Edit Text to add some text of your own or to change the font. This is the place for you to tell your site visitors a little bit about you and your services.